D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...
In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches have yielded survival benefit in patients with metastatic cancer. In one approach, the addition of ...
Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema ...
The Congress on Controversies in Ophthalmology will be held April 4-5 in Seville, Spain.As the name implies, the unique ...
Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...
COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMDCompany confirms topline results for ...
Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback